Nurix missed earnings and revenue badly, but the $700 million Roche upfront arriving next quarter will vault cash to $1.14 billion and fund the leap into Phase 3 trials for lead BTK degrader bexobrutideg. The quarterly flop fades against a transformative collaboration that validates targeted protein degradation as the field's future.

WD-40 demolished earnings expectations with a 49% EPS beat as U.S. sales of its iconic Multi-Use Product surged on expanded distribution and e-commerce momentum, while management raised full-year guidance and authorized a $100 million share buyback.

Simulations Plus crushed EPS expectations by 29% and returned to GAAP profitability with a 7% revenue gain driven by 20% growth in services, positioning the biopharma software maker well ahead of its expected close with Altaris later this year.